Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Study finds Moderna’s COVID-19 vaccine drives a stronger antibody response than Pfizer’s​​

Researchers suspect the results could result from a larger dose of mRNA or a longer window between the prime and boost doses of the vaccine.

By Brian Buntz | August 31, 2021

Pfizer-BioNTech-ModernaResearch published in JAMA found the Moderna’s COVID-19 vaccine drove an antibody response that was more than two times greater than that of Pfizer’s.

Specifically, the Moderna mRNA-1273 vaccine generated post-second-dose antibody levels of 2,881 units per milliliter. Those who received the Pfizer-BioNTech BNT162b2 vaccine had antibody levels measuring 1,108 units per milliliter.

The study involved 1,647 fully vaccinated healthcare workers in Belgium.

Immune protection, however, involves more than antibody levels. Pfizer researchers found that recipients of their vaccine have immune protection 12 days after vaccination when there are low antibody levels, according to a STAT article.

In volunteers who had previously contracted COVID-19, the Moderna vaccine recipients generated antibody levels of 3,836 units per milliliter, while antibody levels in Pfizer-BioNTech vaccine recipients were 1,444 units per milliliter.

Some 688 volunteers received the Moderna vaccine. A total of 959 got the Pfizer-BioNTech vaccine.

The higher antibody levels in Moderna recipients could have resulted from the longer window between doses (28 vs. 21 days) or the larger quantity of mRNA in the Moderna vaccine (100 µg in the Moderna vaccine versus 30 µg in the Pfizer).

Researchers performed serologic testing six to ten weeks after receipt of the second dose of the vaccine.

The study was carried out from April 27 to May 20 — long before the rise of the Delta variant.

The mean age of recipients of the mRNA-1273 vaccine was 43.2 years old. BNT162b2 recipients skewed slightly older with a median age of 44.7.

A separate preprint study also found that the Moderna vaccine appeared to be more effective than the BNT162b2 against the Delta variant.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: BioNTech, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Moderna, Pfizer, SARS-CoV-2
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE